congenital heart disease pediatric population cardiopulmonary bypass Pharmacokinetics Pharmacodynamics
Conditions
Interventions
Blood and Urine sampling.
Sponsors
Erasmus MC
's Gravendijkwal 230
Dept Anesthesiology/Thorax
3015 CE Rotterdam
The Netherlands
Eligibility
Inclusion criteria
Inclusion criteria: All pediatric patients 0-18 years old, stratified for age group, undergoing open heart surgery for congenital heart disease with the use of CPB are candidates for inclusion. The age-groups will be: 1. Neonates 0-30 days old; 2. Infants 30-365 days old; 3. Preschool children aged 1-4 years old; 4. School children aged 4-12 years old; 5. Adolescents aged 12-18 years old.
Exclusion criteria
Exclusion criteria: No informed consent.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| 1. Determination of population PK of midazolam, propofol, sufentanil, pancuronium, ranitidine, furosemide, enoximone and dobutamine in the pediatric population; 2. Determination of the relationship between the PK of the medication and clinical parameters as age, cyanotic or acyanotic cardiac defects, cardiopulmonary bypass system used, pump flow rate, liver and renal function and protein concentrations. | — |
Secondary
| Measure | Time frame |
|---|---|
| Determination of the relationship between PK and the clinical effect of aforementioned medication. DNA analysis will be performed to evaluate the influence of gene polymorphisms on the PD of anesthetic and analgesic medication. | — |
Contacts
Public ContactL. Duininck
Erasmus University Medical Center PO Box 2040
Outcome results
None listed